Stock AMRX AMNEAL PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Amneal Pharmaceuticals, Inc.

Equities

AMRX

US03168L1052

Real-time Estimate Cboe BZX
Other stock markets
 20:55:36 09/05/2024 BST 		5-day change 1st Jan Change
6.475 USD -1.75% Intraday chart for Amneal Pharmaceuticals, Inc. +4.91% +7.33%
05-06 Goldman Sachs Adjusts Amneal Pharmaceuticals Price Target to $8 From $6.25, Maintains Buy Rating MT
05-03 Truist Securities Raises Amneal Pharmaceuticals' Price Target to $9 From $7, Maintains Buy Rating MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Drugmaker Amneal agrees to $270 million U.S. opioid settlement
RE
Sector Update: Health Care Stocks Mixed Pre-Bell Friday
MT
Amneal Pharmaceuticals Q1 Adjusted Earnings, Revenue Climb
MT
(AMRX) AMNEAL PHARMACEUTICALS Forecasts Fiscal Year 2024 EPS Range $0.53 - $0.63
MT
Earnings Flash (AMRX) AMNEAL PHARMACEUTICALS Reports Q1 Revenue $659.2M, vs. Street Est of $619M
MT
Earnings Flash (AMRX) AMNEAL PHARMACEUTICALS Posts Q1 EPS $0.14, vs. Street Est of $0.09
MT
North American Morning Briefing : Apple, Amgen -2-
DJ
Amneal Pharmaceuticals, Inc. Affirms Earnings Guidance for Full Year 2024
CI
Amneal Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Amneal Pharmaceuticals Cleared by FDA to Sell Generic Version of Nasal Spray to Treat Opioid Overdose -- Shares Rise
MT
Amneal Pharmaceuticals Shares Rise 9% After FDA Approves Naloxone Spray
DJ
Amneal Announces U.S. FDA Approval of Over-The-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
CI
Shilpa Medicare Partner Amneal Pharma Launches Ready-to-Use Pemetrexed in US
MT
Amneal Pharmaceuticals Announces Launch of Pemetrexed Injection, 100mg/10 Mg/10 Mg/50 Mg/Ll
CI
Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says
MT
RBC Notes "Positive" Appellate Court Ruling For Bausch Health, But Thinks Market Assigning ~32% BLCO Distribution Odds
MT
TSX ends flat as gold stocks drop, mood cautious ahead of rate decision
RE
Bausch Health Up Near 0.4% In US Premarket After Announcing Patent Lawsuit Against Amneal Pharmaceuticals
MT
Amneal Pharmaceuticals Receives FDA Approval for Ear Infection Treatment
MT
Amneal Pharmaceuticals, Inc Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AMRX Stock
  4. News Amneal Pharmaceuticals, Inc.
  5. Highlights